Literature DB >> 26514815

Nivolumab: a review in advanced squamous non-small cell lung cancer.

Gillian M Keating1.   

Abstract

Nivolumab (Opdivo(®); Nivolumab BMS™) was the first programmed death (PD)-1 immune checkpoint inhibitor to be approved for use in advanced, squamous non-small cell lung cancer (NSCLC) following prior chemotherapy. In the pivotal CheckMate 017 trial, intravenous nivolumab 3 mg/kg every 2 weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC. Nivolumab was also better tolerated than docetaxel in CheckMate 017, and its adverse event profile (which included immune-mediated adverse events) was manageable. In conclusion, nivolumab represents an important advance in previously-treated, advanced, squamous NSCLC.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26514815     DOI： 10.1007/s40265-015-0492-9

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  22 in total

Review 1.  Nivolumab in NSCLC: latest evidence and clinical potential.

Authors:  Raghav Sundar; Byoung-Chul Cho; Julie R Brahmer; Ross A Soo
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

2.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

3.  Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

Authors:  Mario Scartozzi; Paola Mazzanti; Riccardo Giampieri; Rossana Berardi; Eva Galizia; Stefano Gasparini; Lina Zuccatosta; Stefano Cascinu
Journal:  Lung Cancer       Date:  2009-08-06       Impact factor: 5.705

Review 4.  Prognostic and predictive markers for the new immunotherapies.

Authors:  Kathleen M Mahoney; Michael B Atkins
Journal:  Oncology (Williston Park)       Date:  2014-11       Impact factor: 2.990

5.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Authors:  E Massarelli; F Andre; D D Liu; J J Lee; M Wolf; A Fandi; J Ochs; T Le Chevalier; F Fossella; R S Herbst
Journal:  Lung Cancer       Date:  2003-01       Impact factor: 5.705

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Authors:  C Zielinski; S Knapp; C Mascaux; F Hirsch
Journal:  Ann Oncol       Date:  2013-02-07       Impact factor: 32.976

Review 10.  Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.

Authors:  Abdulaziz Al-Farsi; Peter Michael Ellis
Journal:  Front Oncol       Date:  2014-06-27       Impact factor: 6.244
View more
  14 in total

1.  Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism.

Authors:  Hui-Ming Chen; Linus Sun; Ping-Ying Pan; Lu-Hai Wang; Shu-Hsia Chen
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

2.  Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore.

Authors:  Brian Cohen; M Blair Marshall
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2016-06       Impact factor: 9.546

4.  Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.

Authors:  Guoliang Pi; Hanping He; Jianping Bi; Ying Li; Yanping Li; Yong Zhang; Mingwei Wang; Guang Han; Chi Lin
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

5.  CYLD Promotes TNF-α-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells.

Authors:  Xing Lin; Qianshun Chen; Chen Huang; Xunyu Xu
Journal:  Mediators Inflamm       Date:  2016-09-25       Impact factor: 4.711

Review 6.  Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy.

Authors:  Tsukasa Seya; Yohei Takeda; Ken Takashima; Sumito Yoshida; Masahiro Azuma; Misako Matsumoto
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2018       Impact factor: 3.493

7.  The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis.

Authors:  Ping Li; Xuefang Yang; Yumiao Feng; Lijuan Wu; Wei Ma; Gaozhong Ding; Yun Wei; Lan Sun
Journal:  Onco Targets Ther       Date:  2018-10-26       Impact factor: 4.147

8.  Fundamental effects of PD-1 antibody on the body: a brief report.

Authors:  Wei Wang; Bing Liu; Guangxian Liu; Wanfeng Guo
Journal:  Onco Targets Ther       Date:  2016-07-07       Impact factor: 4.147

9.  Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.

Authors:  Junjie Piao; Liyan Chen; Taihao Quan; Longshan Li; Chunji Quan; Yingshi Piao; Tiefeng Jin; Zhenhua Lin
Journal:  Oncotarget       Date:  2016-09-13

10.  A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.

Authors:  Kaja Richard; Jacqueline Weslow; Stephanie L Porcella; Sowmya Nanjappa
Journal:  Cancer Control       Date:  2017 Oct-Dec       Impact factor: 3.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.